Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Raised to $403 at BMO Capital on 4Q Report; '2018 Guidance Above Street With Room to Grow'

January 25, 2018 3:48 PM
BMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $403.00 (from $394.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles